secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2026-02-04T23:59:59+00:00
Accession:  0001213900-26-011826
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity opens Phase 2 trial of stenoparib + temozolomide in relapsed SCLC
--------------------------------------------------------------------------

- Enrollment open at 11 VA sites for NCT06681220; trial fully funded by U.S. Department of Veterans Affairs.
- Phase 2 evaluates stenoparib (dual PARP/WNT inhibitor) plus temozolomide in recurrent small cell lung cancer.
- Study uses a blood-based biomarker to select patients most likely to benefit from the combination.
- Stenoparib's favorable safety profile is cited as key rationale for combination with temozolomide.
- Stenoparib crosses the blood-brain barrier, offering potential for brain metastases common in advanced SCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026011826/0001213900-26-011826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026011826/ea0275506-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-011826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer